DiaMedica Therapeutics Inc.

DMAC ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2018 FY2017
Revenue $500.0K
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $4.5M $3.2M
SG&A Expense $2.7M $1.3M
Operating Income $-6.8M $-4.5M
Operating Margin -1,352.2%
Interest Expense
Pretax Income $-5.7M $-4.3M
Income Tax Expense $80.0K
Net Income $-5.7M $-4.3M
Net Margin -1,146.8%
EPS (Basic) $-0.74 $-0.72
EPS (Diluted) $-0.74 $-0.72
Shares Outstanding (Basic) 12.0M 6.4M
Shares Outstanding (Diluted) 12.0M 6.4M
Dividends Per Share
← Newer Page 2 of 2 Older →